Drug · CHEMBL852

MELPHALAN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. MELPHALAN. Drugs and targets, record CHEMBL852. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL852

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: MELPHALAN; ChEMBL
ChEMBL ID: CHEMBL852; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Alkeran; ChEMBL
Other names: Alanine nitrogen mustard, CB 3025, CB-3025, L-pam, L-phenylalanine mustard, L-sarcolysin, Melfalan, NCI-C04853, NSC-241286, NSC-8806, Phenylalanine mustard, SK 15673, SK-15673, Sarcolycin, l-; ChEMBL
Other form: MELPHALAN HYDROCHLORIDE, CHEMBL1200863; Drugs and targets
DrugBank: DB01042; DrugBank
InChIKey: SGDBTWWWUNNDEQ-LBPRGKRZSA-N; ChEMBL
Open Targets' highest stage: Approval, for 9 of its 140 diseases, from ATC, DailyMed, EMA Human Drugs and TTD; Open Targets

Targets0

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

None in this release.

Diseases140

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
plasma cell myeloma	Approval	DailyMed, EMA Human Drugs and TTD	221	217	https://conductscience.org/library/drugs?q=MONDO_0009693
non-Hodgkin lymphoma	Approval	EMA Human Drugs	53	52	https://conductscience.org/library/drugs?q=MONDO_0018908
myelodysplastic syndrome	Phase 3	ClinicalTrials.gov	48	48	https://conductscience.org/library/drugs?q=MONDO_0018881
acute myeloid leukemia	Approval	EMA Human Drugs	46	45	https://conductscience.org/library/drugs?q=MONDO_0018874
hematopoietic and lymphoid cell neoplasm	Phase 2/3	ClinicalTrials.gov	43	43	https://conductscience.org/library/drugs?q=MONDO_0044881
Hodgkins lymphoma	Approval	EMA Human Drugs	40	39	https://conductscience.org/library/drugs?q=MONDO_0004952
lymphoma	Phase 2	ClinicalTrials.gov	36	36	https://conductscience.org/library/drugs?q=MONDO_0005062
neuroblastoma	Approval	EMA Human Drugs	34	33	https://conductscience.org/library/drugs?q=MONDO_0005072
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	22	22	https://conductscience.org/library/drugs?q=MONDO_0004967
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	19	19	https://conductscience.org/library/drugs?q=MONDO_0018905

1 to 10 of 140Source Open Targets

See all 140 diseases

Trials686

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01818752	Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma	Phase 3	955	2017-08-01	melphalan	Its name	ClinicalTrials.gov
NCT02195479	A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma	Phase 3	706	2018-12-17	melphalan	Its name	ClinicalTrials.gov
NCT00083551	UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy	Phase 3	668	2015-09-22	melphalan	Its name	ClinicalTrials.gov
NCT00567567	Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma	Phase 3	665	2017-06-27	melphalan	Its name	ClinicalTrials.gov
NCT00507416	Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone	Phase 3	502	2014-05-01	melphalan	Its name	ClinicalTrials.gov
NCT00345865	Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	Phase 2	473	2020-07-14	melphalan	Its name	ClinicalTrials.gov
NCT01119066	HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies	Phase 2	422	2022-08-05	melphalan	Its name	ClinicalTrials.gov
NCT00177047	Autologous Transplant for Multiple Myeloma	Phase 2/3	363	2021-11-09	melphalan	Its name	ClinicalTrials.gov
NCT00003816	Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer	Phase 2/3	361	2021-08-13	melphalan	Its name	ClinicalTrials.gov
NCT00602641	Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma	Phase 3	306	2015-06-29	melphalan	Its name	ClinicalTrials.gov

1 to 10 of 686

See all 686 trials

Comparisons in its trials115

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bortezomib, Melphalan, Prednisone vs Carfilzomib, Melphalan, Prednisone: serious adverse events	198 of 470	235 of 474	944	NCT01818752	Trial comparisons
Velcade, Melphalan and Prednisone (VMP) vs Daratumumab, Velcade, Melphalan and Prednisone (D-VMP): deaths from any cause	217 of 356	172 of 350	706	NCT02195479	Trial comparisons
Velcade, Melphalan and Prednisone (VMP) vs Daratumumab, Velcade, Melphalan and Prednisone (D-VMP): serious adverse events	117 of 354	186 of 346	700	NCT02195479	Trial comparisons
Thalidomide vs No Thalidomide: serious adverse events	323 of 323	345 of 345	668	NCT00083551	Trial comparisons
MPT-T vs mPR-R: serious adverse events	110 of 148	88 of 150	298	NCT00602641	Trial comparisons
Myeloablative Conditioning Regimen (MAC) vs Reduced Intensity Conditioning (RIC): Number of Participants With Primary Graft Failure	1 of 132	3 of 133	265	NCT01339910	Trial comparisons
Myeloablative Conditioning Regimen (MAC) vs Reduced Intensity Conditioning (RIC): Number of Participants With Secondary Graft Failure	1 of 132	4 of 133	265	NCT01339910	Trial comparisons
Myeloablative Conditioning Regimen (MAC) vs Reduced Intensity Conditioning (RIC): serious adverse events	21 of 132	16 of 133	265	NCT01339910	Trial comparisons
B-BEAM vs R-BEAM: serious adverse events	11 of 111	6 of 113	224	NCT00329030	Trial comparisons
Busulfan + Melphalan vs Melphalan: Overall Survival (OS)	91 of 104	79 of 98	202	NCT01413178	Trial comparisons

1 to 10 of 115

See all 115 comparisons in its trials

Papers from its trials361

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41249450	RESULT	1	PubMed
39471440	RESULT	1	PubMed
36344419	RESULT	1	PubMed
35511184	RESULT	1	PubMed
34804017	RESULT	1	PubMed
34455741	RESULT	1	PubMed
33832208	RESULT	1	PubMed
33150834	RESULT	1	PubMed
32750127	RESULT	1	PubMed
32518291	RESULT	1	PubMed

1 to 10 of 361

See all 361 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL852

GET https://conductscience.org/api/drugs/v1/CHEMBL852/diseases?page=2

API reference For AI assistants